【摘 要】
:
目的 慢性炎症在糖尿病肾病(DN)的发展中发挥重要作用.间充质干细胞(MSCs)是一类具有免疫调节功能的细胞.本研究旨在探讨骨髓来源的MSC移植能否通过降低炎症反应,减缓糖尿病大鼠肾病进展.
【机 构】
:
四川大学华西医院移植工程与移植免疫重点实验室 四川大学华西医院病理研究室
【出 处】
:
中华医学会糖尿病学分会第十八次全国学术会议
论文部分内容阅读
目的 慢性炎症在糖尿病肾病(DN)的发展中发挥重要作用.间充质干细胞(MSCs)是一类具有免疫调节功能的细胞.本研究旨在探讨骨髓来源的MSC移植能否通过降低炎症反应,减缓糖尿病大鼠肾病进展.
其他文献
Objective To test whether the association between sleep duration,daytime nap duration and osteoporosis varies by sex,menopause and sleep quality.Methods This cross-sectional study was based on two com
Objective Obesity is known to increase the risks of endometrial cancer in postmenopausal women.The mechanisms underlying such associations is still undetermined.Adiponectin is the most abundant adipok
Objective The aim of this study was to estimate the normative reference value of baroreflex sensitivity(BRS),and assess cardiovascular autonomic neuropathy(CAN)prevalence in our cross-sectional datase
Objective Dyslipidemia is strongly associated with raised plasma glucose levels and insulin resistance,and genomewide association studies have identified 95 loci that explain a substantial proportion
Objective The purpose of this study was to evaluate the predictive value of diabetes mellitus(DM)and resting heart rate(HR)in a large sample derived from a Chinese population.Methods We conducted a la
Objective To determine the secular trend of prevalence of Type 2 diabetes and pre-diabetes and related risk factors for diabetes in 3 population-based surveys from 2001 to 2009.Methods We conducted 3
Objectives To compare maternal and fetal outcomes of pregnancy after bariatric surgery with pregnancy of obese women without a history of bariatric surgery.Methods Search methods: PubMed and Embase da
目的 度拉糖肽(Dulaglutide)是每周1次皮下给药的长效胰高血糖素样肽1(GLP-1)受体激动剂.为度拉糖肽广泛用于2型糖尿病(T2DM)人群提供证据,对其在肝功能或肾功能不全受试者中的药代动力学(PK)特征进行研究.方法 进行了两项独立的单剂量开放研究,比较度拉糖肽1.5 mg在肝功能不全(n=15)或肾功能不全(n=32)受试者中,相对于健康受试者(n=11和n=16)的PK特征.两项
目的 使用可重复的标准化代谢测定方法,评估1型或2型糖尿病患者接受Bionica胰岛素治疗(BIT)对呼吸商的改善及BIT治疗的安全性方法 本研究为一项多中心、随机开放、平行对照,为期13周的临床研究,试验组接受BIT治疗,对照组进行追踪访视和对比.入选标准为:(1)确诊为1型或2型糖尿病患者;(2)年龄≥18岁,≤80岁.(3)呼吸商(RQ)<0.8.
目的 探讨2型糖尿病患者应用甘精胰岛素联合阿卡波糖片
与联合沙格列汀的安全性差异.
方法 患糖尿病的夜班车司机84例,分为甘精胰岛素联合阿卡波糖治疗组(阿卡波糖组)43例,甘精胰岛素联合沙格列汀治疗组(沙格列汀组)41例,对比观察治疗3个月后糖化血红蛋白(HbAlc)、体重改变、胰岛素用量、低血糖的发生率,依从性.